Achieve Life Sciences (ACHV)

Executive Summary

Achieve Life Sciences is a late-stage biopharmaceutical company solely focused on developing and commercializing cytisinicline, a plant-based alkaloid for nicotine dependence. With a New Drug Application (NDA) under FDA review for smoking cessation and a PDUFA date of June 20, 2026, the company is on track to potentially introduce the first new FDA-approved smoking cessation pharmacotherapy in nearly two decades. Cytisinicline has demonstrated favorable efficacy and safety in Phase 3 trials, positioning it as a promising alternative to current treatments like varenicline and nicotine replacement therapy. Beyond smoking cessation, Achieve is expanding into vaping cessation with an ongoing Phase 3 trial (NCT07392125) initiated in May 2026, targeting a growing public health concern. The company's singular focus, robust clinical data, and large addressable market make it a high-impact opportunity, albeit with binary regulatory risk.

Upcoming Catalysts (preview)

• Q2 2026FDA PDUFA Decision for Cytisinicline (Smoking Cessation)65% success
• Q2 2026Initiation of Phase 3 Vaping Cessation Trial100% success
• Q2 2026Potential FDA Advisory Committee Meeting for Cytisinicline50% success